Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucagon-like peptide-1 analog
- Development stage
- Preclinical
- Lead developer
- NTT Biopharma
- Modality
- Peptides
- Administration
- Oral
01
Overview
NTT Biopharma is developing an oral glucagon-like peptide-1 (GLP-1) receptor agonist analog for the treatment of Type 2 Diabetes. As a GLP-1 receptor agonist, the drug is designed to mimic the action of endogenous GLP-1, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying to improve glycemic control. This asset is currently in the discovery phase and utilizes an oral peptide formulation, which aims to provide a more convenient administration route compared to traditional injectable GLP-1 therapies.
- Other names
- GLP-1 analogGLP1 analogGLP 1 analog
02
Targets
Beyond the preview
Go deeper on glucagon-like peptide-1 analog.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucagon-like peptide-1 analog.